Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. - Wikidata - awgldk - TriplyDB

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

http://www.wikidata.org/entity/Q34582536

about

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma Systemic Immunotherapy for the Treatment of Brain Metastases In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination Melanoma brain metastases: an unmet challenge in the era of active therapy Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam.Surgical management of melanoma brain metastases in patients treated with immunotherapy.Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.Treatment options for brain metastases from melanoma.Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases.Melanoma-induced brain metastases.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Novel treatments for melanoma brain metastases.Dabrafenib for treatment of BRAF-mutant melanoma.Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.Sequencing brain metastases and opportunities for targeted therapies.Challenges in the delivery of therapies to melanoma brain metastases.Ipilimumab in a Phase II trial of melanoma patients with brain metastases.Measurement of cytotoxic activity in experimental cancer.Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.Gamma knife radiosurgery in the management of malignant melanoma brain metastases.Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis.An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies

P2860

Q26745933-EBEFC281-A6D4-4FEE-83B4-B5848312624F Q26750891-356555C2-E2EE-4F34-9B21-A7A02868BE25 Q26801403-B2093C63-734F-4207-BDC2-1D2B110585B4 Q26995622-AE1C660C-258E-44BB-8C03-20449D74BF4D Q30251581-9819EC2D-DC0A-4939-8571-227EDFD642C3 Q30457624-7A44FE86-9F61-465F-8435-08F182FFBC6B Q34954990-8F96F1B3-AC30-498D-88C8-27C7376D9121 Q36023879-4044F66E-1461-4BF4-9A75-6799633F8041 Q36284501-966AE9B4-A7CF-47A2-8CAE-C3E00CE582E7 Q36618229-39B450F5-5E85-456A-B302-F09B6D7BCAD6 Q36883292-13DABC66-BBA6-4B75-886A-84EB48349149 Q37159517-07C951BD-8BA0-4897-AC04-12A2C120D0D3 Q37414808-98858636-F5F2-473C-9D03-DE9618C7F6F1 Q38146716-42D4C347-E605-4D8C-85C1-6C5DB170DAB6 Q38187117-CD49C313-2286-4AC6-AE18-0F1D9201D226 Q38548397-0D7AE90D-D187-46F2-8091-AE53D7F99501 Q39177404-D277BF43-2BD1-438F-B2ED-C69B581A5CFB Q39331752-234D47C1-A713-4060-8118-EFBD48065119 Q41274844-4B3262D3-C386-418F-9B92-7937A90A0455 Q44733547-DC6EF82E-FFFF-4D61-84E1-12EA2BCD023F Q47653459-1EF75EFC-DFB6-4A62-9B5E-3A58B1E1B435 Q48258912-D7BA1779-4A68-4C9D-AA52-13DC8B0F21DB Q48961952-B5D7137D-08EB-491A-855F-C0AD3C08B1D4 Q55206910-18B24941-AE15-4C7B-AD39-1C5C763EC4B7 Q56892924-6DBA1879-3AA0-4788-93AF-3DAC8B0E36A1 Q57172250-9F8AA4C5-1F87-4723-88D6-194006C3C72E

P2860

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

http://www.wikidata.org/entity/Q34582536

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@ast

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@en

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@nl

type

label

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@ast

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@en

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@nl

prefLabel

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@ast

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@en

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@nl

P1433

Q34582536-8EB2CBDB-6C8F-4412-80D2-80CB8DB7B988

P1476

Q34582536-E54B3E61-6F94-4B39-B559-CA930FB26A72

P2093

Q34582536-04145096-23AF-466D-A23D-789AF2AC2051

Q34582536-54E6210E-77C8-4071-8EA4-C050D8E551F5

Q34582536-5BDD23D3-E18B-4798-B3AB-70FBD5E6EE9B

Q34582536-6C50D175-DE77-4D45-8D98-7381D5482CC4

Q34582536-74EF496C-486A-4445-B5EE-BAA87378C88F

Q34582536-AD951A82-AF5B-44E5-8D28-9E15B8BE7ABF

Q34582536-AE8F9A4E-085A-4D68-B9F6-A8CB50352990

P2860

Q34582536-140681B1-3839-4D77-BEF8-D9438E81A0DB

Q34582536-965EB169-B1B6-4FA5-BCE9-1E96A020FB86

Q34582536-A3C83C75-839B-4BF9-B3D3-3E6F224F1B00

Q34582536-D54CB175-AF52-4026-A117-90B2C9D18868

P304

Q34582536-6875E8A8-8AAC-4320-A219-76563EC7DE6F

P31

Q34582536-7D14F860-2FB6-464E-9F5C-9EC37345B382

P356

Q34582536-3D1AE3FF-397D-4422-A93E-287D38D2E119

P433

Q34582536-E22C5BC3-C95E-4DFC-A4B1-CE6E67607E62

P478

Q34582536-6DCE1A14-8257-430E-A6BB-1D6D9F8FB1E5

P577

Q34582536-5A75535C-D012-4D84-8BC5-7F9B0443A5E8

P5875

Q34582536-073E3CEC-87D9-4E6B-865E-2A0A6D070129

P698

Q34582536-159F6E30-0F72-47D5-ABC6-6DFFD50F1DEA

P932

Q34582536-B444D80C-6F14-447F-A022-C8169601AEB6

P356

00002371-200201000-00009

P1433

Journal of Immunotherapy

P1476

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

@en

P2093

David J Liewehr

http://www.w3.org/2001/XMLSchema#string

Donald E White

http://www.w3.org/2001/XMLSchema#string

Douglas J Schwartzentruber

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Lisa M Guirguis

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

P304

82-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002371-200201000-00009

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11440243

http://www.w3.org/2001/XMLSchema#string

P698

11924913

http://www.w3.org/2001/XMLSchema#string

P932

2424228

http://www.w3.org/2001/XMLSchema#string